What is GenEdit?
GenEdit is a biotechnology firm dedicated to the discovery and development of innovative genetic medicines. At the core of its operations is the NanoGalaxy platform, a proprietary system utilizing non-viral, non-lipid polymer nanoparticles. This technology is designed to facilitate targeted in vivo delivery, addressing one of the most significant hurdles in the field of gene therapy. By providing a versatile delivery mechanism, GenEdit is not only advancing its own internal therapeutic pipeline but also collaborating with industry partners to deliver a wide array of therapeutic payloads. The company's focus on safe and effective delivery systems positions it as a key player in the next generation of biopharmaceutical innovation.
How much funding has GenEdit raised?
GenEdit has raised a total of $118.5M across 4 funding rounds:
Angel/Seed
$8.5M
Series A
$26M
Other Financing Round
$24M
Series B
$60M
Angel/Seed (2018): $8.5M, investors not publicly disclosed
Series A (2021): $26M led by KB Investment, IMM Investment, Lilly, KTB Network, DAYLI Partners, Company K Partners, and Korea Investment Partners
Other Financing Round (2024): $24M supported by Genentech
Series B (2026): $60M featuring STIC Ventures, DSC Investment, Yuanta Investment, Kiwoom Investment, Top Harvest Capital, and Sv Investment
Key Investors in GenEdit
STIC Ventures
STIC Ventures is a regional venture capital manager that focuses on investing in promising businesses to foster economic growth and prosperity across Asia.
DSC Investment
DSC Investment provides comprehensive support for businesses, offering expertise in cloud solutions and digital infrastructure to facilitate operational growth.
Yuanta Investment
Yuanta Investment is a venture firm that specializes in thorough due diligence and strategic planning to maximize the value of its portfolio companies.
What's next for GenEdit?
With the successful closure of its latest funding round, GenEdit is poised to transition into a more intensive phase of clinical development and platform expansion. The company will likely prioritize the optimization of its NanoGalaxy platform to enhance the precision and efficacy of its genetic payloads. Furthermore, the firm is expected to deepen its strategic partnerships, leveraging its unique delivery technology to support external drug development programs. As GenEdit continues to refine its internal pipeline, the focus will remain on navigating the regulatory landscape and demonstrating the clinical utility of its non-viral delivery systems in human health applications.
See full GenEdit company page
